Literature DB >> 24132484

Engineering adenovirus genome by bacterial artificial chromosome (BAC) technology.

Zsolt Ruzsics1, Frederic Lemnitzer, Christian Thirion.   

Abstract

Bacterial artificial chromosomes (BACs) are recombinant DNA molecules designed for propagation of large and instable foreign DNA fragment in Escherichia coli. BACs are used in genetics of large DNA viruses such as herpes and baculoviruses for propagation and manipulation of complex genomic regions or even entire viral genomes in one piece. Viral genomes in BACs are ready for the advanced tools of E. coli genetics. These techniques based on homologous or site-specific recombination allow engineering of virtually any kind of genetic changes. In the recent years, BAC technology was also adapted to manipulation of adenovirus genomes and became an effective alternative to traditional genetic engineering of recombinant adenoviruses.

Entities:  

Mesh:

Year:  2014        PMID: 24132484     DOI: 10.1007/978-1-62703-679-5_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  The amphipathic helix of adenovirus capsid protein VI contributes to penton release and postentry sorting.

Authors:  Ruben Martinez; Pascale Schellenberger; Daven Vasishtan; Cindy Aknin; Sisley Austin; Denis Dacheux; Fabienne Rayne; Alistair Siebert; Zsolt Ruzsics; Kay Gruenewald; Harald Wodrich
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

Review 2.  Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development.

Authors:  Man Teng; Yongxiu Yao; Venugopal Nair; Jun Luo
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

3.  Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses.

Authors:  Martin Mück-Häusl; Manish Solanki; Wenli Zhang; Zsolt Ruzsics; Anja Ehrhardt
Journal:  Nucleic Acids Res       Date:  2015-01-21       Impact factor: 16.971

4.  Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo.

Authors:  Richard Kiener; Markus Fleischmann; Christiane Schwegler; Zsolt Ruzsics; Christian Thirion; Silke Schrödel; Benedikt Asbach; Ralf Wagner
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

Review 5.  Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.

Authors:  Katie Ewer; Sarah Sebastian; Alexandra J Spencer; Sarah Gilbert; Adrian V S Hill; Teresa Lambe
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 6.  Simian adenoviruses as vaccine vectors.

Authors:  Susan J Morris; Sarah Sebastian; Alexandra J Spencer; Sarah C Gilbert
Journal:  Future Virol       Date:  2016-09-15       Impact factor: 1.831

7.  Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.

Authors:  Dennis Lapuente; Jana Fuchs; Jonas Willar; Ana Vieira Antão; Valentina Eberlein; Nadja Uhlig; Leila Issmail; Anna Schmidt; Friederike Oltmanns; Antonia Sophia Peter; Sandra Mueller-Schmucker; Pascal Irrgang; Kirsten Fraedrich; Andrea Cara; Markus Hoffmann; Stefan Pöhlmann; Armin Ensser; Cordula Pertl; Torsten Willert; Christian Thirion; Thomas Grunwald; Klaus Überla; Matthias Tenbusch
Journal:  Nat Commun       Date:  2021-11-26       Impact factor: 14.919

8.  Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs.

Authors:  Patrick Neckermann; Ditte Rahbaek Boilesen; Torsten Willert; Cordula Pertl; Silke Schrödel; Christian Thirion; Benedikt Asbach; Peter Johannes Holst; Ralf Wagner
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 9.  CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses.

Authors:  Ming Yuan; Eika Webb; Nicholas Robert Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2016-03-07       Impact factor: 5.048

Review 10.  The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.

Authors:  Luyao Wang; Yurong Chen; Xinrui Liu; Ziyi Li; Xiangpeng Dai
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.